story of the week
Rolapitant Effectively Prevents Nausea and Vomiting After Highly Emetogenic Chemotherapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Safety and Efficacy of Rolapitant for Prevention of Chemotherapy-Induced Nausea and Vomiting After Administration of Cisplatin-Based Highly Emetogenic Chemotherapy in Patients With Cancer: Two Randomized, Active-Controlled, Double-Blind, Phase 3 Trials
Lancet Oncol 2015 Aug 10;[EPub Ahead of Print], BL Rapoport, MR Chasen, C Gridelli, L Urban, MR Modiano, ID Schnadig, A Poma, S Arora, V Kansra, LS Schwartzberg, RM NavariFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.